ClinConnect ClinConnect Logo
Search / Trial NCT03076697

Smartphone Screening for Eye Diseases

Launched by UNIVERSITY OF MICHIGAN · Mar 6, 2017

Trial Information

Current as of June 26, 2025

Enrolling by invitation

Keywords

Fundus Photography Smartphone Based Photography

ClinConnect Summary

Millions of Americans are at risk for sight-threatening diseases and are either unable to access eye care services or unaware that eye care screening could reduce their risk of vision loss. In addition, there is a national shortage of eye care providers. Primary care providers lack resources to effectively screen for sight-threatening conditions. Of the three leading causes of permanent vision loss and blindness in adults in the United States (namely, diabetic retinopathy, glaucoma, and age-related macular degeneration), all three diseases largely affect structures in what is referred to as...

Gender

ALL

Eligibility criteria

  • Inclusion Criteria:
  • Any patient at least seen in the ophthalmology clinic with eye diseases as a result of diabetes, glaucoma, age related macular degeneration, retinopathy of prematurity, of who is willing to participate in the study.
  • Exclusion Criteria:
  • Patients with eye diseases other than what is listed in inclusion criteria.

About University Of Michigan

The University of Michigan, a leading academic institution renowned for its commitment to advancing healthcare and medical research, serves as a prominent clinical trial sponsor. With a robust infrastructure that supports innovative research initiatives, the university leverages its multidisciplinary expertise to conduct a wide array of clinical trials aimed at improving patient outcomes and advancing medical knowledge. Through its state-of-the-art facilities and collaborative environment, the University of Michigan fosters partnerships between researchers, clinicians, and industry leaders, ensuring the development of cutting-edge therapies and interventions that address pressing health challenges.

Locations

Patients applied

0 patients applied

Trial Officials

Yannis Paulus, MD

Principal Investigator

University of Michigan

Timeline

First submit

Trial launched

Trial updated

Estimated completion

Not reported

Similar Trials